147 related articles for article (PubMed ID: 8463174)
21. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Thadepalli H; Chuah SK; Gollapudi S
Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
[TBL] [Abstract][Full Text] [Related]
22. In vitro susceptibilities of the Bacteroides fragilis group species: change in isolation rates significantly affects overall susceptibility data.
Aldridge KE; O'Brien M
J Clin Microbiol; 2002 Nov; 40(11):4349-52. PubMed ID: 12409429
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy of cefoperazone, cefoperazone plus sulbactam, ciprofloxacin, clindamycin, metronidazole, and penicillin G against anaerobic bacteria in an animal model.
Moody JA; Fasching CE; Sinn LM; Gerding DN; Peterson LR
J Lab Clin Med; 1990 Feb; 115(2):190-5. PubMed ID: 1967626
[TBL] [Abstract][Full Text] [Related]
24. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals.
Hecht DW; Osmolski JR; O'Keefe JP
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S357-60. PubMed ID: 8324147
[TBL] [Abstract][Full Text] [Related]
25. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
[TBL] [Abstract][Full Text] [Related]
26. Comparative study of clindamycin, imipenem, oxacillin and vancomycin in the infected granuloma pouch model.
Brauner E; Gorbach S; Davey P
J Antimicrob Chemother; 1989 Jun; 23(6):891-8. PubMed ID: 2759932
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy of 10 antimicrobial agents in experimental infections with Bacteroides fragilis.
Joiner K; Lowe B; Dzink J; Bartlett JG
J Infect Dis; 1982 Apr; 145(4):561-8. PubMed ID: 7069236
[TBL] [Abstract][Full Text] [Related]
28. Bacteroides fragilis group: trends in resistance.
Fille M; Mango M; Lechner M; Schaumann R
Curr Microbiol; 2006 Feb; 52(2):153-7. PubMed ID: 16450067
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess.
Fu KP; Lasinski ER; Zoganas HC; Kimble EF; Konopka EA
J Antimicrob Chemother; 1984 Dec; 14(6):633-40. PubMed ID: 6520063
[TBL] [Abstract][Full Text] [Related]
30. Bacteroides fragilis: current susceptibilities, mechanisms of drug resistance, and principles of antimicrobial therapy.
Cuchural GJ; Tally FP
Drug Intell Clin Pharm; 1986; 20(7-8):567-73. PubMed ID: 3488895
[TBL] [Abstract][Full Text] [Related]
31. Significance of encapsulated Bacteroides melaninogenicus and Bacteroides fragilis groups in mixed infections.
Brook I; Walker RI
Infect Immun; 1984 Apr; 44(1):12-5. PubMed ID: 6142862
[TBL] [Abstract][Full Text] [Related]
32. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.
Bartlett JG; Dezfulian M; Joiner K
Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635
[TBL] [Abstract][Full Text] [Related]
33. Transfer of tetracycline or clindamycin resistance among strains of Bacteroides fragilis in experimental abscesses.
Butler E; Joiner KA; Malamy M; Bartlett JC; Tally FP
J Infect Dis; 1984 Jul; 150(1):20-4. PubMed ID: 6747344
[TBL] [Abstract][Full Text] [Related]
34. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
Aldridge KE; Ashcraft D; Cambre K; Pierson CL; Jenkins SG; Rosenblatt JE
Antimicrob Agents Chemother; 2001 Apr; 45(4):1238-43. PubMed ID: 11257040
[TBL] [Abstract][Full Text] [Related]
35. Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.
Snydman DR; Jacobus NV; McDermott LA; Goldstein EJ; Harrell L; Jenkins SG; Newton D; Patel R; Hecht DW
Anaerobe; 2017 Feb; 43():21-26. PubMed ID: 27867083
[TBL] [Abstract][Full Text] [Related]
36. In-vitro sensitivity tests and in-vivo efficacy of cephalosporins against Bacteroides fragilis.
Brook I
J Antimicrob Chemother; 1990 Jul; 26(1):158-61. PubMed ID: 2211440
[No Abstract] [Full Text] [Related]
37. Comparative in-vitro activity of cefoperazone/sulbactam and 11 other agents against multidrug resistant Bacteroides fragilis group species.
Goldstein EJ; Citron DM
J Antimicrob Chemother; 1996 Oct; 38(4):733-7. PubMed ID: 8937969
[TBL] [Abstract][Full Text] [Related]
38. Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains.
Katsandri A; Papaparaskevas J; Pantazatou A; Petrikkos GL; Thomopoulos G; Houhoula DP; Avlamis A
J Clin Microbiol; 2006 Sep; 44(9):3465-7. PubMed ID: 16954304
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the E-test for susceptibility testing of the Bacteroides fragilis group. Danish study group.
Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
APMIS; 1994 Jun; 102(6):446-50. PubMed ID: 8068304
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
